{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=34",
    "query": {
      "intervention": "Part 3",
      "page": 34
    },
    "page_size": 10
  },
  "pagination": {
    "page": 34,
    "page_size": 10,
    "total_count": 4019,
    "total_pages": 402,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=35&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=33&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T18:47:54.559Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07220785",
      "title": "Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Lipodystrophy"
      ],
      "interventions": [
        {
          "name": "Mibavademab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2026-03-13",
      "completion_date": "2028-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Dallas, Texas",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220785"
    },
    {
      "nct_id": "NCT03582215",
      "title": "Assessment of the Human Systemic Absorption of Sunscreen Ingredients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Exposure to Sunscreen Ingredients"
      ],
      "interventions": [
        {
          "name": "Part 1: Cream",
          "type": "DRUG"
        },
        {
          "name": "Part 1: Lotion",
          "type": "DRUG"
        },
        {
          "name": "Part 1: Spray 1",
          "type": "DRUG"
        },
        {
          "name": "Part 1: Spray 2",
          "type": "DRUG"
        },
        {
          "name": "Part 2: Lotion",
          "type": "DRUG"
        },
        {
          "name": "Part 2: Aerosol Spray",
          "type": "DRUG"
        },
        {
          "name": "Part 2: Nonaerosol Spray",
          "type": "DRUG"
        },
        {
          "name": "Part 2: Pump Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Food and Drug Administration (FDA)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 72,
      "start_date": "2018-07-18",
      "completion_date": "2019-02-18",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03582215"
    },
    {
      "nct_id": "NCT03267940",
      "title": "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cholangiocarcinoma Non-resectable",
        "Cholangiocarcinoma, Intrahepatic",
        "Cholangiocarcinoma, Extrahepatic",
        "Gallbladder Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "PEGPH20",
          "type": "DRUG"
        },
        {
          "name": "CIS",
          "type": "DRUG"
        },
        {
          "name": "GEM",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2017-10-02",
      "completion_date": "2019-11-11",
      "has_results": true,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03267940"
    },
    {
      "nct_id": "NCT05812274",
      "title": "Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-05-31",
      "completion_date": "2025-10-24",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 4,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05812274"
    },
    {
      "nct_id": "NCT05311618",
      "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Non Small Cell Lung Cancer",
        "Cervical Cancer",
        "Endocervical Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Bladder Urothelial Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Ovarian Cancer",
        "Renal Cell Carcinoma",
        "Prostate Cancer",
        "Melanoma",
        "Mesothelioma",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "NGM438",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA ®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2022-05-11",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2024-04-01",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05311618"
    },
    {
      "nct_id": "NCT06445959",
      "title": "Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mutant IDH1 Inhibitor Olutasidenib"
      ],
      "interventions": [
        {
          "name": "Olutasidenib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine/cedazuridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2024-08-29",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Westwood, Kansas • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445959"
    },
    {
      "nct_id": "NCT02125721",
      "title": "Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cystinuria"
      ],
      "interventions": [
        {
          "name": "Tiopronin 1g per day",
          "type": "DRUG"
        },
        {
          "name": "Tiopronin 2g per day",
          "type": "DRUG"
        },
        {
          "name": "Tiopronin 3g per day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-06",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2021-08-23",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02125721"
    },
    {
      "nct_id": "NCT02486406",
      "title": "A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection"
      ],
      "interventions": [
        {
          "name": "Ombitasvir/paritaprevir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Dasabuvir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Ombitasvir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Paritaprevir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Dasabuvir mini tablet",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-10-28",
      "completion_date": "2020-11-19",
      "has_results": true,
      "last_update_posted_date": "2021-10-05",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02486406"
    },
    {
      "nct_id": "NCT05242458",
      "title": "A Study of Ustekinumab Treatment in Children With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 545,
      "start_date": "2022-03-21",
      "completion_date": "2023-05-22",
      "has_results": false,
      "last_update_posted_date": "2025-05-13",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05242458"
    },
    {
      "nct_id": "NCT07402226",
      "title": "Systemic Sclerosis DIet for GastrointESTinal Symptoms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Sclerosis (SSc)"
      ],
      "interventions": [
        {
          "name": "Diet 1: Restriction of fermentable carbohydrates",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Diet 2: Elimination of foods harmful to gut barrier and microbiome",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Diet 3: Regular meal patterns, soluble fiber, and portion control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-03-16",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-11T18:47:54.559Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07402226"
    }
  ]
}